KTX 0101

Drug Profile

KTX 0101

Alternative Names: Sodium beta-hydroxybutyrate

Latest Information Update: 27 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BTG
  • Developer KetoCytonyx
  • Class Ketone bodies; Neuroprotectants; Small molecules
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cognition disorders

Most Recent Events

  • 27 Sep 2011 No development reported - Phase-I for Cognition disorders in United Kingdom (IV)
  • 14 Dec 2004 Preclinical data from a media release have been added to the adverse events, pharmacodynamic and pharmacokinetic sections
  • 13 Dec 2004 KetoCytonyx has completed a phase I trial in Cognition disorders in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top